ACADIA Pharmaceuticals Inc. (ACAD) Research

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

Market snapshot

Symbol
ACAD
Price
$21.62
Day change
+0.09%
Market cap
$3.7B
P/E ratio
9.81x
52-week range
19.69-28.35
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$33.67

Recent news

  • Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback

    Bank of America upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to 'Buy' from 'Neutral', arguing that a recent pullback in the stock has created a more attractive risk-reward profile for investors. The analysts maintained a $29 price objective on the shares, which traded up 6% at $22 on Wednesday afternoon, and wrote that the roughly 25% decline in the stock is “not related to fundamentals and more related to YTD macro factors.

  • Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback

    Bank of America upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to 'Buy' from 'Neutral', arguing that a recent pullback in the stock has created a more...

Peer companies

  • ADMA Biologics, Inc. (ADMA)
  • Belite Bio, Inc (BLTE)
  • Crinetics Pharmaceuticals, Inc. (CRNX)
  • Dyne Therapeutics, Inc. (DYN)
  • Immunovant, Inc. (IMVT)
  • Ligand Pharmaceuticals Incorporated (LGND)
  • Mirum Pharmaceuticals, Inc. (MIRM)
  • Praxis Precision Medicines, Inc. (PRAX)

Recent insider activity

  • BAKER BROS. ADVISORS LP — A-Award (18622 shares) on 2026-05-29
  • BAKER BROS. ADVISORS LP — A-Award (18622 shares) on 2026-05-29
  • BAKER BROS. ADVISORS LP — A-Award (32008 shares) on 2026-05-29
  • HARRIGAN EDMUND — M-Exempt (8107 shares) on 2026-05-29
  • HARRIGAN EDMUND — A-Award (16004 shares) on 2026-05-29

Open ACADIA Pharmaceuticals Inc. (ACAD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.